BR112018009754A8 - bloqueador de canal de sódio - Google Patents

bloqueador de canal de sódio

Info

Publication number
BR112018009754A8
BR112018009754A8 BR112018009754A BR112018009754A BR112018009754A8 BR 112018009754 A8 BR112018009754 A8 BR 112018009754A8 BR 112018009754 A BR112018009754 A BR 112018009754A BR 112018009754 A BR112018009754 A BR 112018009754A BR 112018009754 A8 BR112018009754 A8 BR 112018009754A8
Authority
BR
Brazil
Prior art keywords
sodium channel
channel blocker
present
usefully
prevention
Prior art date
Application number
BR112018009754A
Other languages
English (en)
Other versions
BR112018009754A2 (pt
BR112018009754B1 (pt
Inventor
Ho Lee Chun
Shin Kim Hyo
Lee Hyung-Geun
Kim Il-Hwan
Sung YOON Ji
JUNG Myunggi
Ah Jun Sun
Kim Sung-Young
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of BR112018009754A2 publication Critical patent/BR112018009754A2/pt
Publication of BR112018009754A8 publication Critical patent/BR112018009754A8/pt
Publication of BR112018009754B1 publication Critical patent/BR112018009754B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

a presente invenção relaciona-se a um composto representado pela fórmula química, ou um sal farmaceuticamente aceitável do mesmo. o composto, de acordo com a presente invenção, pode ser utilizado de forma útil para prevenção ou tratamento de doenças relacionadas ao bloqueador de canal de sódio.
BR112018009754-3A 2015-11-13 2016-11-11 Composto tendo função bloqueadora de canal de sódio, sua composição farmacêutica e seu uso BR112018009754B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150159637 2015-11-13
KR10-2015-0159637 2015-11-13
PCT/KR2016/013029 WO2017082688A1 (ko) 2015-11-13 2016-11-11 소디움 채널 차단제

Publications (3)

Publication Number Publication Date
BR112018009754A2 BR112018009754A2 (pt) 2018-11-06
BR112018009754A8 true BR112018009754A8 (pt) 2019-02-26
BR112018009754B1 BR112018009754B1 (pt) 2024-01-23

Family

ID=58695815

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018009754-3A BR112018009754B1 (pt) 2015-11-13 2016-11-11 Composto tendo função bloqueadora de canal de sódio, sua composição farmacêutica e seu uso

Country Status (30)

Country Link
US (1) US10227338B2 (pt)
EP (1) EP3375782B1 (pt)
JP (1) JP6559894B2 (pt)
KR (1) KR102245930B1 (pt)
CN (1) CN108349963B (pt)
AU (1) AU2016351526B2 (pt)
BR (1) BR112018009754B1 (pt)
CA (1) CA3003119C (pt)
CL (1) CL2018001281A1 (pt)
CO (1) CO2018005064A2 (pt)
EC (1) ECSP18038014A (pt)
ES (1) ES2821962T3 (pt)
HK (1) HK1251229A1 (pt)
HR (1) HRP20201695T1 (pt)
HU (1) HUE052569T2 (pt)
MA (1) MA43231B1 (pt)
MX (1) MX2018005940A (pt)
MY (1) MY194015A (pt)
NZ (1) NZ742069A (pt)
PE (1) PE20181301A1 (pt)
PH (1) PH12018500999A1 (pt)
PL (1) PL3375782T3 (pt)
PT (1) PT3375782T (pt)
RS (1) RS60927B1 (pt)
RU (1) RU2705578C1 (pt)
SA (1) SA518391540B1 (pt)
SG (1) SG11201803867TA (pt)
SI (1) SI3375782T1 (pt)
TN (1) TN2018000157A1 (pt)
WO (1) WO2017082688A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019114964A (ru) * 2016-10-17 2020-11-17 Дженентек, Инк. Терапевтические средства и способы их применения
WO2020052509A1 (zh) * 2018-09-10 2020-03-19 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
CN112759559B (zh) * 2019-11-06 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
PT1612208E (pt) * 2001-03-12 2011-10-12 Ono Pharmaceutical Co Composto de n-fenilarilsulfonamida, composição farmacêutica compreendendo o composto como ingrediente activo, intermediários de síntese para o composto e processos para a sua preparação
JP2006290791A (ja) * 2005-04-11 2006-10-26 Astellas Pharma Inc アゾール置換スルホニルベンゼン誘導体
US20090221581A1 (en) * 2005-05-25 2009-09-03 Philipp Wabnitz Methods of treating pain
US7888345B2 (en) 2006-06-09 2011-02-15 Merck Sharp & Dohme Corp. Benzaepinones as sodium channel blockers
CA2695613A1 (en) * 2006-12-19 2008-06-26 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
JP2008290791A (ja) * 2007-05-22 2008-12-04 Funai Electric Co Ltd 画像形成装置
US8124610B2 (en) * 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
PT2385938E (pt) * 2009-01-12 2015-06-02 Pfizer Ltd Derivados de sulfonamida
EP2593432B1 (en) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
US9481677B2 (en) 2011-10-31 2016-11-01 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
EP2788332A1 (en) 2011-12-07 2014-10-15 Amgen, Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
CA2857603C (en) 2011-12-15 2016-08-02 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
WO2013177224A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
US9376429B2 (en) * 2012-10-15 2016-06-28 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers, preparation method thereof and use thereof
US20170145003A1 (en) * 2014-02-27 2017-05-25 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel

Also Published As

Publication number Publication date
EP3375782A4 (en) 2019-05-15
MY194015A (en) 2022-11-08
HRP20201695T1 (hr) 2020-12-25
HUE052569T2 (hu) 2021-05-28
RS60927B1 (sr) 2020-11-30
RU2705578C1 (ru) 2019-11-08
SG11201803867TA (en) 2018-06-28
JP2018533606A (ja) 2018-11-15
MA43231B1 (fr) 2020-08-31
WO2017082688A1 (ko) 2017-05-18
ES2821962T3 (es) 2021-04-28
TN2018000157A1 (en) 2019-10-04
CO2018005064A2 (es) 2018-06-20
MX2018005940A (es) 2018-08-14
KR20170056461A (ko) 2017-05-23
PT3375782T (pt) 2020-08-05
EP3375782B1 (en) 2020-07-29
CA3003119A1 (en) 2017-05-18
CA3003119C (en) 2019-10-22
SA518391540B1 (ar) 2021-04-06
SI3375782T1 (sl) 2020-10-30
CL2018001281A1 (es) 2018-08-31
BR112018009754A2 (pt) 2018-11-06
AU2016351526A1 (en) 2018-05-17
PH12018500999A1 (en) 2019-01-28
CN108349963A (zh) 2018-07-31
ECSP18038014A (es) 2018-05-31
PE20181301A1 (es) 2018-08-09
AU2016351526B2 (en) 2019-02-21
PL3375782T3 (pl) 2021-02-22
US10227338B2 (en) 2019-03-12
US20180346459A1 (en) 2018-12-06
HK1251229A1 (zh) 2019-01-25
CN108349963B (zh) 2021-03-30
JP6559894B2 (ja) 2019-08-14
BR112018009754B1 (pt) 2024-01-23
NZ742069A (en) 2019-08-30
KR102245930B1 (ko) 2021-04-29
EP3375782A1 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12019500480A1 (en) Pyridine compound
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
MY197698A (en) Oxysterols and methods of use thereof
MD4659B1 (ro) Polimorf al inhibitorilor SYK
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
BR112017013936A2 (pt) inibidores de bace1 seletivos.
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
MX2019002369A (es) Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
BR112018009754A2 (pt) bloqueador de canal de sódio
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
EA201690908A1 (ru) Пиразолопиримидиновые соединения
AR115865A2 (es) Compuestos terapéuticos
NZ748746A (en) Pyrazolopyrimidine derivatives as kinase inhibitor
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: IN THERAPEUTICS (KR)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/11/2016, OBSERVADAS AS CONDICOES LEGAIS